The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding. 2510
What this version reported
Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.↗↗↗
Trial records: NCT06297603
Reader guide in this version
Key takeaway
Retatrutide is an experimental peptide from Eli Lilly that activates the receptors for three hormones: GIP, GLP-1 and glucagon.1,4,5 It is not an approved drug. FDA states that it is not a component of any FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.2 Published randomized trials report weight loss and lower blood sugar, including a 338-person Phase 2 obesity trial and a 537-person Phase 3 diabetes trial. Several other Phase 3 trials are registered on ClinicalTrials.gov.3,5,6,9 FDA says it has warned companies for marketing retatrutide to consumers, including products falsely labeled as being for research purposes.2
At a glance
- What it is
- An investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.1,5
- FDA status
- Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.2
- Human evidence
- Randomized trials reported in journals: two Phase 2 trials and one Phase 3 diabetes trial. Other Phase 3 trials are registered.3,4,5,6
- Evidence strength
- Large randomized human trials
What is retatrutide?
Retatrutide is an experimental peptide being developed by Eli Lilly and Company, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile. It is also known by its development code, LY3437943.1
The published trial reports describe it as a single molecule that activates the receptors for three hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.4,5
How is retatrutide thought to work?
The 2023 New England Journal of Medicine report describes retatrutide as a triple-hormone-receptor agonist, meaning one molecule that acts on three hormone receptors.3
The sources reviewed here do not establish how much each of the three receptors contributes to the effects reported in trials.3,4,5
What do human studies show?
In the Phase 2 obesity trial, 338 adults with obesity, or overweight with a weight-related condition, were randomized to retatrutide or placebo. At 48 weeks, average body-weight change ranged from −8.7% to −24.2% across the retatrutide groups, compared with −2.1% with placebo.3
In that trial, gastrointestinal events were the most common adverse events, and increases in heart rate peaked at 24 weeks before declining.3
A Phase 2 trial of 281 adults with type 2 diabetes reported changes in HbA1c, a measure of long-term blood sugar, ranging from −0.43 to −2.02 percentage points across the retatrutide groups at 24 weeks, compared with −0.01 for placebo and −1.41 for the active comparator.4
In TRANSCEND-T2D-1, a Phase 3 trial of 537 adults whose type 2 diabetes was not controlled by diet and exercise, HbA1c fell by 1.69 to 1.94 percentage points across the retatrutide groups at 40 weeks, compared with 0.81 with placebo. Gastrointestinal events were common, and 2% to 5% of participants in the retatrutide groups stopped because of adverse events, compared with none on placebo.5
That report recorded two deaths in one retatrutide group, which the authors considered unrelated to study treatment.5
These trials followed participants for 24 to 48 weeks for their main results, which does not show long-term outcomes, rare harms, or what happens after treatment stops.3,4,5
What the evidence base contains
- Large randomized human trial A 48-week double-blind, randomized, placebo-controlled Phase 2 trial in 338 adults with obesity, or overweight with a weight-related condition, published in The New England Journal of Medicine.3
- Controlled human trial A randomized, double-blind Phase 2 trial with placebo and active comparator groups in 281 adults with type 2 diabetes at 42 U.S. centers, published in The Lancet.4
- Large randomized human trial TRANSCEND-T2D-1, a 40-week double-blind, randomized, placebo-controlled Phase 3 trial in 537 adults with type 2 diabetes, published in The Lancet.5
- Registered trial without results Phase 3 trials in obesity with cardiovascular disease (NCT05882045) and in obesity with type 2 diabetes or sleep apnea (NCT05929079), listed as completed in registry records updated July 30, 2026. Their results are not part of the sources cited here.6,7
- Registered trial without results A Phase 3 trial in people with cardiovascular or chronic kidney disease (NCT06383390), listed as active, not recruiting in its August 24, 2026 registry record.9
Evidence-strength label: Large randomized human trials. How this label is assigned
Is retatrutide FDA-approved?
No. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.2
The same page states that retatrutide and cagrilintide cannot be used in compounding under federal law.2
FDA says it has warned telehealth companies for marketing unapproved drugs such as retatrutide, including directly to consumers, distributors of active ingredients for selling retatrutide to compounders, and outsourcing facilities for repackaging it.2
FDA also says it has warned companies that sold unapproved drugs containing retatrutide falsely labeled as being for research purposes or not for human consumption, and it urges consumers to avoid these products, which it says are of unknown quality.2
Retatrutide remains in clinical trials. None of the sources reviewed here reports an approval of retatrutide in any country.2,10
Timeline
- Results of two Phase 2 trials, in obesity and in type 2 diabetes, are published.3,4
- Results of TRANSCEND-T2D-1, a Phase 3 trial in type 2 diabetes, are published in The Lancet.5
- FDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date.2
What is still unknown?
Whether the weight and blood-sugar results lead to fewer heart attacks, strokes or other long-term complications: the published trials measured weight and HbA1c over 24 to 48 weeks.3,5
What the completed Phase 3 trials found: their results are not part of the sources cited on this page.6,7,8
What is in retatrutide products marketed outside clinical trials, which FDA describes as unapproved and of unknown quality.2
Sources for this version
- 1Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 4Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗
The Lancet · Official source · Source checked November 14, 2026
- 5Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗
The Lancet · Official source · Source checked November 14, 2026
- 6ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 7ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 8ClinicalTrials.gov record NCT05929066 · retained source version 2026-08-21:fa2b7b67fa10d746247b3082eeaba2f5a16212dc2a870697f3b8369f43983d27 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 9ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 10ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026